KHẢO SÁT KẾT QUẢ KIỂM SOÁT MỤC TIÊU NỒNG ĐỘ LDL-c HUYẾT THANH Ở BỆNH NHÂN HỘI CHỨNG MẠCH VÀNH MẠN ĐÃ ĐIỀU TRỊ ROSUVASTATIN 10MG TẠI BỆNH VIỆN TIM MẠCH THÀNH PHỐ CẦN THƠ NĂM 2021-2022

Abstract

Background: Dyslipidemia is a common cardiovascular risk factor in clinical practice, increasing dangerous cardiovascular complications.Rosuvastatin is a statin commonly recommended for use in many countries worldwide. For a better assessment of the hypolipideic effects of the blood, especially LDL-c of rosuvastatin medium content and the safety of the drug in patients with chronic coronary syndrome (CCS) is necessary. Objectives: To determine the rate of serum LDL-c goal failure and investigate the factors associated with the serum LDL-c target failure rate in patients with chronic coronary syndrome treated with rosuvastatin 10mg ≥4 weeks. Materials and methods: A cross-sectional study on 206 patients diagnosed with CCS treated with rosuvastatin 10mg ≥4 weeks at Can Tho Cardiovascular Hospital from April 2021 to March 2022. Results: The percentage of patients who did not reach the target LDL-c concentration <1.8mmol/l accounted for 68.4%. Female gender, BMI, overweight and obesity, and physical inactivity were associated with the rate of not reaching the target LDL-c concentration <1.8mmol/l (p<0.05). Conclusions: The proportion of patients who did not match the target of LDL-c concentration <1.8mmol/l accounted for 68.4%. Female gender, BMI, overweight and obesity, and physical inactivity were associated with the rate of not reaching the target LDL-c concentration <1.8 mmol/l.